TSG-6 produced by hMSCs delays the onset of autoimmune diabetes by suppressing Th1 development and enhancing tolerogenicity

Diabetes

Volumn 62, Issue 6, 2013, Pages 2048-2058

  Kota, Daniel J ^a   Wiggins, Lindsey L ^a   Yoon, Nara ^a   Lee, Ryang Hwa ^a  

^a TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HERMES ANTIGEN; INTERLEUKIN 10; INTERLEUKIN 12; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR ALPHA; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA STIMULATED GENE 6; UNCLASSIFIED DRUG;

ADOPTIVE TRANSFER; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTING CELL; ARTICLE; AUTOIMMUNE DISEASE; CELL MATURATION; CONTROLLED STUDY; CYTOKINE RELEASE; FEMALE; HUMAN; HUMAN CELL; INSULIN DEPENDENT DIABETES MELLITUS; INSULITIS; MESENCHYMAL STEM CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TH1 CELL;

ANIMALS; ANTIGEN-PRESENTING CELLS; BLOTTING, WESTERN; CELL ADHESION MOLECULES; DIABETES MELLITUS, TYPE 1; FEMALE; HUMANS; IMMUNOPRECIPITATION; MESENCHYMAL STROMAL CELLS; MICE; MICE, KNOCKOUT; REAL-TIME POLYMERASE CHAIN REACTION; T-LYMPHOCYTES, REGULATORY; TH1 CELLS;

EID: 84878221854     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db12-0931     Document Type: Article

References (50)

1. Gorus FK, Pipeleers DG; Belgian Diabetes Registry. Prospects for predicting and stopping the development of type 1 of diabetes. Best Pract Res Clin Endocrinol Metab 2001;15:371-389 (Pubitemid 32916268)
2. Bingley PJ, Bonifacio E, Gale EA. Can we really predict IDDM? Diabetes 1993;42:213-220 (Pubitemid 23045023)
3. Sherr J, Sosenko J, Skyler JS, Herold KC. Prevention of type 1 diabetes: the time has come. Nat Clin Pract Endocrinol Metab 2008;4:334-343 (Pubitemid 351733474)
4. Atkinson MA, Maclaren NK, Luchetta R. Insulitis and diabetes in NOD mice reduced by prophylactic insulin therapy. Diabetes 1990;39:933-937
5. Zhang ZJ, Davidson L, Eisenbarth G, Weiner HL. Suppression of diabetes in nonobese diabetic mice by oral administration of porcine insulin. Proc Natl Acad Sci USA 1991;88:10252-10256 (Pubitemid 21915813)
6. O'Brien BA, Harmon BV, Cameron DP, Allan DJ. Nicotinamide prevents the development of diabetes in the cyclophosphamide-induced NOD mouse model by reducing beta-cell apoptosis. J Pathol 2000;191:86-92 (Pubitemid 30235654)
7. Harrison LC, Honeyman MC, Steele CE, et al. Pancreatic beta-cell function and immune responses to insulin after administration of intranasal insulin to humans at risk for type 1 diabetes. Diabetes Care 2004;27:2348-2355 (Pubitemid 39281384)
8. Skyler JS, Krischer JP, Wolfsdorf J, et al. Effects of oral insulin in relatives of patients with type 1 diabetes: The Diabetes Prevention Trial -Type 1. Diabetes Care 2005;28:1068-1076 (Pubitemid 40616615)
9. Gale EA, Bingley PJ, Emmett CL, Collier T; European Nicotinamide Diabetes Intervention Trial (ENDIT) Group. European Nicotinamide Diabetes Intervention Trial (ENDIT): a randomised controlled trial of intervention before the onset of type 1 diabetes. Lancet 2004;363:925-931
10. Kolb H, Burkart V. Nicotinamide in type 1 diabetes. Mechanism of action revisited. Diabetes Care 1999;22(Suppl. 2):B16-B20 (Pubitemid 29107143)
11. Lee RH, Pulin AA, Seo MJ, et al. Intravenous hMSCs improve myocardial infarction in mice because cells embolized in lung are activated to secrete the anti-inflammatory protein TSG-6. Cell Stem Cell 2009;5: 54-63
12. Oh JY, Roddy GW, Choi H, et al. Anti-inflammatory protein TSG-6 reduces inflammatory damage to the cornea following chemical and mechanical injury. Proc Natl Acad Sci USA 2010;107:16875-16880
13. Roddy GW, Oh JY, Lee RH, et al. Action at a distance: systemically administered adult stem/progenitor cells (MSCs) reduce inflammatory damage to the cornea without engraftment and primarily by secretion of TNF-α stimulated gene/protein 6. Stem Cells 2011;29:1572-1579
14. Choi H, Lee RH, Bazhanov N, Oh JY, Prockop DJ. Anti-inflammatory protein TSG-6 secreted by activated MSCs attenuates zymosan-induced mouse peritonitis by decreasing TLR2/NF-{kappa}B signaling in resident macrophages. Blood 2011;118:330-338
15. Jun HS, Yoon CS, Zbytnuik L, van Rooijen N, Yoon JW. The role of macrophages in T cell-mediated autoimmune diabetes in nonobese diabetic mice. J Exp Med 1999;189:347-358 (Pubitemid 29063256)
16. Dahlén E, Dawe K, Ohlsson L, Hedlund G. Dendritic cells and macrophages are the first and major producers of TNF-alpha in pancreatic islets in the nonobese diabetic mouse. J Immunol 1998;160:3585-3593 (Pubitemid 28164755)
17. Hutchings P, Rosen H, O 'Reilly L, Simpson E, Gordon S, Cooke A. Transfer of diabetes in mice prevented by blockade of adhesion-promoting receptor on macrophages. Nature 1990;348:639-642 (Pubitemid 120015126)
18. Poligone B, Weaver DJ Jr, Sen P, Baldwin AS Jr, Tisch R. Elevated NFkappaB activation in nonobese diabetic mouse dendritic cells results in enhanced APC function. J Immunol 2002;168:188-196 (Pubitemid 34014118)
19. Alleva DG, Johnson EB, Wilson J, Beller DI, Conlon PJ. SJL and NOD macrophages are uniquely characterized by genetically programmed, elevated expression of the IL-12(p40) gene, suggesting a conserved pathway for the induction of organ-specific autoimmunity. J Leukoc Biol 2001;69:440-448 (Pubitemid 32221449)
20. Liu J, Beller D. Aberrant production of IL-12 by macrophages from several autoimmune-prone mouse strains is characterized by intrinsic and unique patterns of NF-kappa B expression and binding to the IL-12 p40 promoter. J Immunol 2002;169:581-586 (Pubitemid 34686182)
21. Csorba TR, Lyon AW, Hollenberg MD. Autoimmunity and the pathogenesis of type 1 diabetes. Crit Rev Clin Lab Sci 2010;47:51-71
22. Yoon JW, Jun HS. Autoimmune destruction of pancreatic beta cells. Am J Ther 2005;12:580-591
23. Abbas AK, Murphy KM, Sher A. Functional diversity of helper T lymphocytes. Nature 1996;383:787-793 (Pubitemid 26372655)
24. Seder RA, Gazzinelli R, Sher A, Paul WE. Interleukin 12 acts directly on CD4+ T cells to enhance priming for interferon gamma production and diminishes interleukin 4 inhibition of such priming. Proc Natl Acad Sci USA 1993;90:10188-10192 (Pubitemid 23328277)
25. Lesley J, Gál I, Mahoney DJ, et al. TSG-6 modulates the interaction between hyaluronan and cell surface CD44. J Biol Chem 2004;279:25745-25754 (Pubitemid 38756838)
26. Smith-Garvin JE, Koretzky GA, Jordan MS. T cell activation. Annu Rev Immunol 2009;27:591-619
27. Brawand P, Fitzpatrick DR, Greenfi eld BW, Brasel K, Maliszewski CR, De Smedt T. Murine plasmacytoid pre-dendritic cells generated from Flt3 ligand-supplemented bone marrow cultures are immature APCs. J Immunol 2002;169:6711-6719 (Pubitemid 36899255)
28. van Kooten C, Banchereau J. CD40-CD40 ligand. J Leukoc Biol 2000;67:2-17 (Pubitemid 30046812)
29. Cella M, Scheidegger D, Palmer-Lehmann K, Lane P, Lanzavecchia A, Alber G. Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation. J Exp Med 1996;184:747-752 (Pubitemid 26324129)
30. Coudronniere N, Villalba M, Englund N, Altman A. NF-kappa B activation induced by T cell receptor/CD28 costimulation is mediated by protein kinase C-theta. Proc Natl Acad Sci USA 2000;97:3394-3399 (Pubitemid 30183313)
31. Sun Z, Arendt CW, Ellmeier W, et al. PKC-theta is required for TCR-induced NF-kappaB activation in mature but not immature T lymphocytes. Nature 2000;404:402-407 (Pubitemid 30164343)
32. Trembleau S, Penna G, Gregori S, Gately MK, Adorini L. Deviation of pancreas-infi ltrating cells to Th2 by interleukin-12 antagonist administration inhibits autoimmune diabetes. Eur J Immunol 1997;27:2330-2339 (Pubitemid 27404318)
33. Trembleau S, Penna G, Bosi E, Mortara A, Gately MK, Adorini L. Interleukin 12 administration induces T helper type 1 cells and accelerates autoimmune diabetes in NOD mice. J Exp Med 1995;181:817-821
34. Ma L, Qian S, Liang X, et al. Prevention of diabetes in NOD mice by administration of dendritic cells deficient in nuclear transcription factorkappaB activity. Diabetes 2003;52:1976-1985 (Pubitemid 36919789)
35. Huet S, Groux H, Caillou B, Valentin H, Prieur AM, Bernard A. CD44 contributes to T cell activation. J Immunol 1989;143:798-801 (Pubitemid 19203800)
36. Ilangumaran S, Briol A, Hoessli DC. CD44 selectively associates with active Src family protein tyrosine kinases Lck and Fyn in glycosphingolipidrich plasma membrane domains of human peripheral blood lymphocytes. Blood 1998;91:3901-3908 (Pubitemid 28225759)
37. Palacios EH, Weiss A. Function of the Src-family kinases, Lck and Fyn, in T-cell development and activation. Oncogene 2004;23:7990-8000 (Pubitemid 39468856)
38. Ilangumaran S, Borisch B, Hoessli DC. Signal transduction via CD44: role of plasma membrane microdomains. Leuk Lymphoma 1999;35:455-469 (Pubitemid 30015645)
39. Baranova NS, Nilebäck E, Haller FM, et al. The inflammation- associated protein TSG-6 cross-links hyaluronan via hyaluronan-induced TSG-6 oligomers. J Biol Chem 2011;286:25675-25686
40. Jaeckel E, Mpofu N, Saal N, Manns MP. Role of regulatory T cells for the treatment of type 1 diabetes mellitus. Horm Metab Res 2008;40:126-136 (Pubitemid 351363424)
41. Madec AM, Mallone R, Afonso G, et al. Mesenchymal stem cells protect NOD mice from diabetes by inducing regulatory T cells. Diabetologia 2009;52:1391-1399
42. Fiorina P, Jurewicz M, Augello A, et al. Immunomodulatory function of bone marrow-derived mesenchymal stem cells in experimental autoimmune type 1 diabetes. J Immunol 2009;183:993-1004
43. Tarbell KV, Petit L, Zuo X, et al. Dendritic cell-expanded, islet-specific CD4 + CD25+ CD62L+ regulatory T cells restore normoglycemia in diabetic NOD mice. J Exp Med 2007;204:191-201 (Pubitemid 46148769)
44. Prockop DJ. Repair of tissues by adult stem/progenitor cells (MSCs): controversies, myths, and changing paradigms. Mol Ther 2009;17:939-946
45. Németh K, Leelahavanichkul A, Yuen PS, et al. Bone marrow stromal cells attenuate sepsis via prostaglandin E(2)-dependent reprogramming of host macrophages to increase their interleukin-10 production. Nat Med 2009;15:42-49
46. Meisel R, Zibert A, Laryea M, Göbel U, Däubener W, Dilloo D. Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation. Blood 2004;103:4619-4621 (Pubitemid 38745993)
47. Groh ME, Maitra B, Szekely E, Koç ON. Human mesenchymal stem cells require monocyte-mediated activation to suppress alloreactive T cells. Exp Hematol 2005;33:928-934 (Pubitemid 40982660)
48. Ortiz LA, Dutreil M, Fattman C, et al. Interleukin 1 receptor antagonist mediates the antiinflammatory and antifibrotic effect of mesenchymal stem cells during lung injury. Proc Natl Acad Sci USA 2007;104:11002-11007 (Pubitemid 47175216)
49. Yagi H, Soto-Gutierrez A, Navarro-Alvarez N, et al. Reactive bone marrow stromal cells attenuate systemic inflammation via sTNFR1. Mol Ther 2010;18:1857-1864
50. Gepts W, De Mey J. Islet cell survival determined by morphology. An immunocytochemical study of the islets of Langerhans in juvenile diabetes mellitus. Diabetes 1978;27(Suppl. 1):251-261 (Pubitemid 8303582)